Skip to main content

Lineage Cell Therapeutics, Inc.

LCTX
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000876343

No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.

13F holders, Q1 2021

Institutional positions in Lineage Cell Therapeutics, Inc. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
102
No complete 13F data for Q4 2020
Shares held
60.3M
No complete 13F data for Q4 2020
Total value
$141.8M
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting LCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 102 institutions
Q1 2021: 102 institutionsQ2 2021: 115 institutionsQ3 2021: 115 institutionsQ4 2021: 124 institutionsQ1 2022: 109 institutionsQ2 2022: 100 institutionsQ3 2022: 104 institutionsQ4 2022: 106 institutionsQ1 2023: 116 institutionsQ2 2023: 107 institutionsQ3 2023: 104 institutionsQ4 2023: 115 institutionsQ1 2024: 116 institutionsQ2 2024: 113 institutionsQ3 2024: 114 institutionsQ4 2024: 126 institutionsQ1 2025: 127 institutionsQ2 2025: 129 institutionsQ3 2025: 112 institutionsQ4 2025: 123 institutionsQ1 2026: 130 institutionsQ2 2026: 131 institutions
Value heldQ1 2021: $141.8M
Q1 2021: $141.8MQ2 2021: $208.5MQ3 2021: $191.7MQ4 2021: $182.0MQ1 2022: $112.3MQ2 2022: $102.7MQ3 2022: $73.1MQ4 2022: $76.2MQ1 2023: $104.7MQ2 2023: $106.6MQ3 2023: $89.1MQ4 2023: $82.5MQ1 2024: $138.3MQ2 2024: $94.2MQ3 2024: $85.6MQ4 2024: $53.8MQ1 2025: $49.7MQ2 2025: $88.4MQ3 2025: $148.6MQ4 2025: $169.8MQ1 2026: $176.5MQ2 2026: $152.7M
Institutions holding LCTX and their total value by quarter
QuarterHoldersValue
Q2 2026131$152.7M
Q1 2026130$176.5M
Q4 2025123$169.8M
Q3 2025112$148.6M
Q2 2025129$88.4M
Q1 2025127$49.7M
Q4 2024126$53.8M
Q3 2024114$85.6M
Q2 2024113$94.2M
Q1 2024116$138.3M
Q4 2023115$82.5M
Q3 2023104$89.1M
Q2 2023107$106.6M
Q1 2023116$104.7M
Q4 2022106$76.2M
Q3 2022104$73.1M
Q2 2022100$102.7M
Q1 2022109$112.3M
Q4 2021124$182.0M
Q3 2021115$191.7M
Q2 2021115$208.5M
Q1 2021102$141.8M

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding Lineage Cell Therapeutics, Inc..

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding LCTX in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Group Inc5,560,056$13.1M0.00%––
Broadwood Capital Inc34,005,379$79.9M4.29%––